Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Regulator which is able to repress transcription, possibly via its interaction with a multiprotein chromatin remodeling complex that modifies the chromatin. Additionally we are shipping Chromosome 11 Open Reading Frame 30 Proteins (3) and many more products for this protein.
Showing 10 out of 37 products:
Human Polyclonal C11orf30 Primary Antibody for WB - ABIN653429
Esparza-Gordillo, Weidinger, Fölster-Holst, Bauerfeind, Ruschendorf, Patone, Rohde, Marenholz, Schulz, Kerscher, Hubner, Wahn, Schreiber, Franke, Vogler, Heath, Baurecht, Novak, Rodriguez, Illig, Lee-Kirsch, Ciechanowicz, Kurek, Piskackova, Macek, Lee, Ru: A common variant on chromosome 11q13 is associated with atopic dermatitis. in Nature genetics 2009
Show all 4 references for ABIN653429
Human Polyclonal C11orf30 Primary Antibody for EIA, WB - ABIN952079
Mavaddat, Dunning, Ponder, Easton, Pharoah: Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer. in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2009
Show all 4 references for ABIN952079
identify a novel substoichiometric interactor of the complex, transcription factor ZNF131 (show ZNF131 Antibodies), which recruits EMSY to a large number of active, H3K4me3 marked promoters.
Eosinophilic esophagitis was associate with increased expression of C11orf30.
The association of higher levels of expression of C11orf30 may be involved in transcription repression of interferon (show IFNA Antibodies)-stimulated genes, and its association with sensitization to multiple allergens suggest that this locus is highly relevant for atopy.
Our study demonstrated that EMSY played an oncogenic role in the progression of ovarian cancer cells and EMSY might be a promising target for the treatment
Univariate analysis revealed a significant positive association between EMSY expression and lymph node metastasis, larger tumor size, as well as a non-significant relation with increased risk of recurrence.
EMSY is recruited to the miR (show MLXIP Antibodies)-31 promoter by the DNA binding factor ETS-1 (show ETS1 Antibodies), and it represses miR (show MLXIP Antibodies)-31 transcription by delivering the H3K4me3 demethylase (show MBD2 Antibodies) JARID1b/PLU-1 (show KDM5B Antibodies)/KDM5B (show KDM5B Antibodies)
Akt1 (show AKT1 Antibodies) regulates the interferon (show IFNA Antibodies) response through phosphorylation of the transcriptional repressor EMSY
There are 2 independent signals, one in C11orf30 and the other in LRRC32, that are strongly associated with serum IgE levels. C11orf30-LRRC32 region may represent a common locus for atopic diseases via pathways involved in regulation of serum IgE levels
EMSY amplification does occur independently of CCND1 (show CCND1 Antibodies) amplification in a minority of familial breast cancers, supporting its role as a possible breast cancer oncogene (show RAB1A Antibodies)
EMSY amplification may mimic BRCA2 (show BRCA2 Antibodies) deficiency, at least by overriding RPA (show RPA1 Antibodies) and PALB2 (show PALB2 Antibodies), crippling the BRCA2 (show BRCA2 Antibodies)/RAD51 (show RAD51 Antibodies) complex at DNA-damage and replication/transcription sites
Regulator which is able to repress transcription, possibly via its interaction with a multiprotein chromatin remodeling complex that modifies the chromatin. Its interaction with BRCA2 suggests that it may play a central role in the DNA repair function of BRCA2.
chromosome 11 open reading frame 30
, EMSY protein
, protein EMSY